The following tables present a summary of the Company’s reporting segments for the three months and six months ended June 30, 2021 and 2020, respectively (unaudited) (Details) - USD ($)			3 Months Ended		6 Months Ended
	Dec. 31, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Segment Reporting Information [Line Items]
REVENUE, net			$ 4,011,304	$ 3,926,342	$ 8,119,836	$ 8,589,552
COST OF GOODS SOLD			3,870,632	4,683,835	7,512,580	8,370,879
Gross (Loss) Profit			140,672	(757,493)	607,256	218,673
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES			7,131,644	5,653,092	13,051,118	11,707,463
RESEARCH AND DEVELOPMENT			2,232,776	3,085,824	4,494,098	5,122,556
IMPAIRMENT EXPENSE - GOODWILL	$ 3,629,010	$ 3,143,200				3,143,200
IMPAIRMENT EXPENSE - CONTRACT COST				1,750,000		1,750,000
IMPAIRMENT EXPENSE - CIP			9,347		9,347
Loss from Operations			(9,233,095)	(11,246,409)	(16,947,307)	(21,504,546)
OTHER INCOME (EXPENSE)
INTEREST EXPENSE			(44,947)	(32,925)	(84,272)	(71,212)
OTHER INCOME			7,886	16,621	24,089	39,676
CHANGE IN FAIR VALUE OF WARRANT LIABILITIES			(43,574)	(1,662,000)	(7,685,474)	1,365,000
Total Other Income (Expense), net			(80,635)	(1,678,304)	(7,745,657)	1,333,464
Net (Loss) Before Income Taxes			(9,313,730)	(12,924,713)	(24,692,964)	(20,171,082)
Drug Development and Commercialization [Member]
Segment Reporting Information [Line Items]
REVENUE, net			1,275,474	721,435	2,608,153	1,228,719
COST OF GOODS SOLD			1,796,242	1,840,402	3,641,480	3,573,185
Gross (Loss) Profit			(520,768)	(1,118,967)	(1,033,327)	(2,344,466)
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES			4,934,491	3,008,585	8,452,542	6,311,817
RESEARCH AND DEVELOPMENT			2,196,721	2,926,108	4,446,464	4,962,840
IMPAIRMENT EXPENSE - GOODWILL
IMPAIRMENT EXPENSE - CONTRACT COST				1,750,000		1,750,000
IMPAIRMENT EXPENSE - CIP
Loss from Operations			(7,651,980)	(8,803,660)	(13,932,333)	(15,369,123)
OTHER INCOME (EXPENSE)
INTEREST EXPENSE			(2,900)	(1,490)	(4,784)	(1,490)
OTHER INCOME			1,900	9,602	3,351	32,657
CHANGE IN FAIR VALUE OF WARRANT LIABILITIES			(43,574)	(1,662,000)	(7,685,474)	1,365,000
Total Other Income (Expense), net			(44,574)	(1,653,888)	(7,686,907)	1,396,167
Net (Loss) Before Income Taxes			(7,696,554)	(10,457,548)	(21,619,240)	(13,972,956)
Compounded Pharmaceuticals [Member]
Segment Reporting Information [Line Items]
REVENUE, net			2,735,830	3,204,907	5,511,683	7,360,833
COST OF GOODS SOLD			2,074,390	2,843,433	3,871,100	4,797,694
Gross (Loss) Profit			661,440	361,474	1,640,583	2,563,139
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES			2,197,153	2,644,507	4,598,576	5,395,646
RESEARCH AND DEVELOPMENT			36,055	159,716	47,634	159,716
IMPAIRMENT EXPENSE - GOODWILL						3,143,200
IMPAIRMENT EXPENSE - CONTRACT COST
IMPAIRMENT EXPENSE - CIP			9,347		9,347
Loss from Operations			(1,581,115)	(2,442,749)	(3,014,974)	(6,135,423)
OTHER INCOME (EXPENSE)
INTEREST EXPENSE			(42,047)	(31,435)	(79,488)	(69,722)
OTHER INCOME			5,986	7,019	20,738	7,019
CHANGE IN FAIR VALUE OF WARRANT LIABILITIES
Total Other Income (Expense), net			(36,061)	(24,416)	(58,750)	(62,703)
Net (Loss) Before Income Taxes			$ (1,617,176)	$ (2,467,165)	$ (3,073,724)	$ (6,198,126)